BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Core Insights - BriaCell Therapeutics Corp. has entered into a clinical supply agreement with BeiGene, Ltd. to evaluate the safety and efficacy of Bria-OTS™ in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for advanced heavily pretreated metastatic breast cancer [1][2] - The Bria-OTS™ platform is positioned as a next-generation off-the-shelf therapy with enhanced potency, building on the success of Bria-IMT™, which has shown clinical benefits in patients resistant to checkpoint inhibitors [2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [3]